HOME >> MEDICINE >> NEWS
New drug to treat enlarged prostate developed at UCL

Millions of men stand to benefit from a discovery by UCL scientists that could provide a breakthrough in the treatment of enlargement of the prostate (BPH). The UCL team has developed a new drug, Rho-kinase inhibitor that, in preliminary tests, has been found to treat the condition by both relaxing the prostate and stopping the growth of cells within it. Their findings are set out in the current issue of the Journal of Urology.

BPH affects approximately 85% of men over the age of 50 and causes frequent urination and irritation due to the obstruction of urine flow. The drugs currently available for treatment of BPH aim to either relax the prostrate or to reduce its size as two separate actions, and also have undesired hormonal effects. These effects, along with the need to take two separate treatments, often lead to problems of patient compliance. The discovery by the UCL scientists is novel in that this new drug can both relax the prostate and stop it from growing, with virtually no hormonal side effects.

Dr Selim Cellek, who led the investigation as a collaborative work between UCL's Wolfson Institute for Biomedical Research and its Institute of Urology and Nephrology, said: "We are very excited by this discovery, as it is a medical breakthrough which represents a major advance in treating a condition that affects such a large proportion of the population. We are still at the development stages and more research will be required before the new treatment becomes available. The next step will be to develop links with investors interested in developing this drug for the treatment of BPH.

"Research has shown that this type of compound can also be used to treat erectile dysfunction (impotence). The future for this line of research is therefore promising since men with an enlarged prostate often suffer from impotence. "

Malcolm Grant, UCL Provost, said: "The conversion of scientific results into new medicines is one of the main aims of th
'"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-207-679-9728
University College London
27-Nov-2003


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Chronic pain treatments more effective when taken together, new study shows
4. Brain activity prior to treatment flags vulnerability to antidepressant side effects
5. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
6. OHSU scientists test medication to treat involuntary weight loss
7. Cultural and social factors influence prostate cancer treatment
8. Research offers hope of new treatments for liver damage
9. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
10. Risky surgery not always necessary to treat cervical disease
11. Stanford patient is first to test new treatment for peripheral arterial disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug treat enlarged prostate developed UCL

(Date:7/28/2014)... An estimated 68,000 women and men ... and prostate cancers – an aggressive form of the ... other parts of the body, such as the lungs, ... University College of Medicine have developed a compound ... progression by blocking tumor cells from “re-seeding.” Their discovery ...
(Date:7/28/2014)... Dallas, TX (PRWEB) July 28, 2014 ... Madrid vs. AS Roma tickets in Dallas, TX at ... on July 24th in the USA and it is an ... teams from around the world including teams from La Liga, ... 2014 teams that will battle it out on the pitch ...
(Date:7/28/2014)... Ticket Down is a dependable source for ... at the Sun Life Stadium in early September. The ... Brazil has is one that has continues to go on. ... on a consistent basis. The rivalry between South America ... recent 2014 World Cup. To the delight of soccer ...
(Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... have dementia and heart rhythm irregularities are more likely to ... found. In fact, the study of more than 16,000 ... percent more likely to get a pacemaker than those without ... study is why folks with dementia are so much more ...
(Date:7/28/2014)... The Brooke Jackman Foundation ... than 200,000 books to children and families in need ... Brooke’s Cooks, a new initiative designed to promote literacy, ... at-risk children and their families in the New York ... nutrition information workshops, cooking demonstrations and readings. BJF, in ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
(Date:7/28/2014)... 28, 2014 Concord Medical Services Holdings Limited ... ), a leading specialty hospital management solution provider and ... imaging centers in China , today ... Directors declared a special cash dividend of US$0.30 per ... on the Company,s outstanding ordinary shares. The total expense ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
(Date:7/28/2014)... CARLSBAD, Calif. , July 28, 2014  Isis ... following webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and ... / 7:30 a.m. PTWhere: www.isispharm.com How:Live on the ... you are unable to participate during the live event, ... a limited time at www.isispharm.com . ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
Cached News: